Clinical Trial Update: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Sofosbuvir/Velpatasvir fixed-dose combination for 12 weeks in adults with chronic Hepatitis C infection and compensated cirrhosis; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• Sofosbuvir/Velpatasvir Fixed Dose Combination (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-04-20